Pear Therapeutics, Inc.

Everyone, welcome to the Pair Therapeutics third quarter 2022 earnings conference call. My name is Elizabeth and I will be your operator today. All lines have been placed on mute to prevent background noise. This call is being recorded. A replay of the webcast will be available in the investors section of the company's website approximately two hours after the completion of the call and will be archived for 30 days. I will now turn the call over to your host, Mira Murphy, Senior Director of Corporate Communications.

Thank you, Elizabeth. Welcome to our third quarter earnings call, and thank you for joining us today. With me today are Cory McCann, our President and Chief Executive Officer, Chris Guifre, our Chief Financial Officer and Chief Operating Officer, Erin Brenner, our Chief Product Development Officer, Yuri Nerevich, our Chief Medical Officer, Ronan O'Brien, our General Counsel, and Julia Strandberg, our Chief Commercial Officer. I'll turn it over to Ronan for the safe harbor statement.

Good afternoon. Some of the statements we make in today's call may constitute forward-looking statements. This includes statements concerning our future business operating results, management intentions, beliefs, and expectations about future results, events, strategies, operating plans, and performance or financial condition. And statements regarding proposed federal legislation regarding PPPs all of which are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as amended. Actual results may differ materially from those indicated by these forward-looking statements due to a variety of important factors. Additional information regarding these factors is included in our annual report on Form 10-K and quarterly report on Form 10-Q filed with the SEC. except as required by law, PEAR assumes no obligation to update or revise these forward-looking statements, even if actual results or future expectations change materially. With that, I'll hand it off to Corey.